Dosing and Administration Protocols

Based on available clinical trial evidence, astaxanthin dosing protocols vary depending on the intended application and study design. However, the current evidence base provides limited specific dosing information from the trials listed.

Clinical Trial Protocols

The completed clinical trials (NCT06511960, NCT06247137, NCT03807050) have investigated astaxanthin supplementation effects, but detailed dosing protocols from these studies are not available in the provided evidence. One completed phase 2 trial (NCT06429059) included astaxanthin as part of a personalized treatment approach, though specific dosing information is not provided.

Research Context

Recent research has focused on various delivery methods and formulations:

Covalently crosslinked chitosan-astaxanthin nanoparticles for enhanced bioavailability in colitis treatment
Combination approaches with other compounds (such as astaxanthin with naringin)
Food-based delivery systems including 3D-printed formulations

One recent study examined 28-day astaxanthin supplementation in taekwondo athletes, though the specific dosing protocol is not detailed in the available evidence.

Evidence Limitations

The current evidence does not provide sufficient detail on standardized dosing protocols, optimal duration of treatment, or administration guidelines across different therapeutic applications. Most studies appear to be investigating astaxanthin's mechanisms of action and delivery methods rather than establishing definitive clinical dosing recommendations.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Dosing and administration of astaxanthin should be determined by a qualified healthcare provider based on individual patient factors, intended use, and current clinical evidence.

Astaxanthin

Member access required